Skip to main content
. Author manuscript; available in PMC: 2020 Nov 1.
Published in final edited form as: Cardiol Clin. 2019 Aug 26;37(4):365–384. doi: 10.1016/j.ccl.2019.07.003

Figure 8.

Figure 8.

Management proposal for blood pressure (BP) control of cancer patients undergoing chemotherapy with hypertension risk. As outlined in the text, we propose that patients on VEGF inhibitor therapy should be treated toward a goal of <130 mmHg systolic (2017 hypertension guideline) and <120 mmHg systolic ideally (SPRINT trial target). Two steps toward reaching this goal are to be pursued: (1) treatment of contributing and aggravating factors and (2) antihypertensive therapy by comorbidity. From Touyz RM, Herrmann SMS, Herrmann J. Vascular toxicities with VEGF inhibitor therapies-focus on hypertension and arterial thrombotic events. J Am Soc Hypertens. 2018;12(6):409–425; with permission.